Q2 2026 Baxter International Inc Earnings Call Transcript
Key Points
- Second quarter organic revenue growth of 5% exceeded expectations, driven by broad-based operational performance across all segments and divisions.
- Strong double-digit growth in drug compounding and continued robust performance in advanced surgery (12% growth) highlight key growth drivers.
- Positive free cash flow generation of $181 million in Q2 and $257 million year-to-date, reflecting improved working capital and strengthening financial flexibility.
- Progress on the Baxter GPS continuous improvement program, with over 400 events completed and hundreds more planned, driving efficiency and execution.
- Innovation momentum with new product launches like PeerView, Vest APX Acute Care, and Dynamo smart stretcher, expanding market offerings and customer value.
- Adjusted EPS declined 5% year-over-year to $0.56, impacted by higher manufacturing costs and unfavorable prior-year cost comparisons.
- Novum IQ LVP infusion pump remains under shipment and installation hold due to field actions, with ongoing regulatory engagement and no timeline for resolution.
- Supply constraints persist in injectables and certain premixed products, particularly from a contract manufacturer, pressuring pharmaceutical portfolio performance.
- Gross margin decreased 210 basis points to 38.6%, driven by higher cost inventory roll-through and tariff impacts, partially offset by a one-time tariff refund.
- Full-year organic sales growth guidance raised to only 2%-3%, reflecting cautious outlook amid macroeconomic uncertainty and potential hospital capital spending slowdown.
Good morning, ladies and gentlemen, and welcome to Baxter International's second quarter 2026 earnings conference call. Your lines will remain in a listen-only mode until the question-and-answer segment of today's call. At that time, if you have a question, you will need to press the star 1 key on your touch-tone phone. If anyone should require assistance during the conference, please press star then 0 on your touch-tone phone.
As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.
I would now like to turn the call over to Mr. Kevin Moran, Vice President, Investor Relations at Baxter International. Mr. Moran, you may begin.
Good morning and welcome. Today, we'll discuss Baxter's second quarter results along with our updated financial outlook for the full year 2026.
This morning, a press release was issued
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
